Teresa M. Petrella

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

Jacob Schachter, Antoni Ribas, Georgina V. Long et al. · The Lancet · 2017 · 1.2K citations

Medicine, Oncology, Pharmacotherapy +17

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

Caroline Robert, Antoni Ribas, Jacob Schachter et al. · The Lancet Oncology · 2019 · 1.2K citations

Medicine, Dermatology, Oncology +14

Exercise for People with Cancer: A Clinical Practice Guideline

Roanne Segal, Caroline Zwaal, E. Green et al. · Current Oncology · 2017 · 276 citations · Full text

Medicine, Oncology, Rehabilitation Medicine +17

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609

Ahmad A. Tarhini, Sandra J. Lee, F. Stephen Hodi et al. · Journal of Clinical Oncology · 2019 · 177 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial

Jun Guo, Richard D. Carvajal, Reinhard Dummer et al. · Annals of Oncology · 2017 · 166 citations · Full text

Medicine, Oncology, Pharmacology +16